Aaron T Zhao1, Anthony D Sung2. 1. Trinity College of Arts and Sciences, Duke University, Durham, NC, USA. 2. Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University, Box 3961 Med Ctr, Durham, NC, 27710, USA. anthony.sung@duke.edu.
Abstract
PURPOSE OF REVIEW: Recent medical advances have allowed a greater number of older patients to undergo hematopoietic stem cell transplantation (HSCT) and participate in HSCT trials. In this review, we outline recent advances in HSCT that have made this possible, general setbacks, and their effects on the landscape of HSCT trials in older adults. RECENT FINDINGS: Reduced-intensity conditioning regimens and a more physiological approach to transplant candidate selection have given older patients an opportunity to participate in HSCT trials. However, difficulties in allogeneic donor selection, post-transplant complications, and the misalignment of trial goals with patient goals may pose challenges for future trial recruitment and success. While increasing amounts of evidence show that older adults may benefit from participation in HSCT trials, clinicians, investigators, and patients must carefully weigh the benefits with potential repercussions.
PURPOSE OF REVIEW: Recent medical advances have allowed a greater number of older patients to undergo hematopoietic stem cell transplantation (HSCT) and participate in HSCT trials. In this review, we outline recent advances in HSCT that have made this possible, general setbacks, and their effects on the landscape of HSCT trials in older adults. RECENT FINDINGS: Reduced-intensity conditioning regimens and a more physiological approach to transplant candidate selection have given older patients an opportunity to participate in HSCT trials. However, difficulties in allogeneic donor selection, post-transplant complications, and the misalignment of trial goals with patient goals may pose challenges for future trial recruitment and success. While increasing amounts of evidence show that older adults may benefit from participation in HSCT trials, clinicians, investigators, and patients must carefully weigh the benefits with potential repercussions.
Authors: Joy H Lewis; Meredith L Kilgore; Dana P Goldman; Edward L Trimble; Richard Kaplan; Michael J Montello; Michael G Housman; José J Escarce Journal: J Clin Oncol Date: 2003-04-01 Impact factor: 44.544
Authors: Lori Muffly; Marcelo C Pasquini; Michael Martens; Ruta Brazauskas; Xiaochun Zhu; Kehinde Adekola; Mahmoud Aljurf; Karen K Ballen; Ashish Bajel; Frederic Baron; Minoo Battiwalla; Amer Beitinjaneh; Jean-Yves Cahn; Mathew Carabasi; Yi-Bin Chen; Saurabh Chhabra; Stefan Ciurea; Edward Copelan; Anita D'Souza; John Edwards; James Foran; Cesar O Freytes; Henry C Fung; Robert Peter Gale; Sergio Giralt; Shahrukh K Hashmi; Gerhard C Hildebrandt; Vincent Ho; Ann Jakubowski; Hillard Lazarus; Marlise R Luskin; Rodrigo Martino; Richard Maziarz; Philip McCarthy; Taiga Nishihori; Rebecca Olin; Richard F Olsson; Attaphol Pawarode; Edward Peres; Andrew R Rezvani; David Rizzieri; Bipin N Savani; Harry C Schouten; Mitchell Sabloff; Matthew Seftel; Sachiko Seo; Mohamed L Sorror; Jeff Szer; Baldeep M Wirk; William A Wood; Andrew Artz Journal: Blood Date: 2017-07-03 Impact factor: 22.113
Authors: Thomas J Hwang; Daniel Carpenter; Julie C Lauffenburger; Bo Wang; Jessica M Franklin; Aaron S Kesselheim Journal: JAMA Intern Med Date: 2016-12-01 Impact factor: 21.873
Authors: Mina S Sedrak; Rachel A Freedman; Harvey J Cohen; Hyman B Muss; Aminah Jatoi; Heidi D Klepin; Tanya M Wildes; Jennifer G Le-Rademacher; Gretchen G Kimmick; William P Tew; Kevin George; Simran Padam; Jennifer Liu; Andrew R Wong; Andrea Lynch; Benjamin Djulbegovic; Supriya G Mohile; William Dale Journal: CA Cancer J Clin Date: 2020-10-01 Impact factor: 508.702